Response

I need a response for this case study:

In Mrs. Allen’s case, ACC/AHA guideline is applicable, especially in the context of the intervention of CVD. Although the primary focus of the guideline is prevention, there are alternative aspects of the framework that suit the health status and situation of Mrs. Allen (Leening & Ikram, 2018). A multidisciplinary team will dissect issues that are relevant to the patient, such as barriers to access to care, social-economic risk concerns, and cultural influences relating to her African American background, race and ethnicity, and, most importantly, the health goals.

                        The 68-year-old patient has no significant safety concerns for a high-intensity statin. The patient requires medication despite MI history. In situations involving MI and acute coronary syndromes, the ASCVD guideline recommends categorization into a distinctive statin benefit group (Leening & Ikram, 2018). In terms of specificity, Mrs. Allen should take daily dosages that help to lower LDL-C by an average of 50% in the high-intensity category. She requires 80 mg of Atorvastatin, while the low-intensity minimum is 10 mg. Crestor in the form of Rosuvastatin should be 40 mg or a moderate of 10 mg. Additional considerations include lovastatin 40 mg and Fluvastatin at 40 mg two times a day (Ross, Shah, & Leeper, 2016). Safety considerations and appropriate dosage are paramount requirements in the ACC/AHA guideline. 

                She needs as well take antiplatelet medications, such as Plavix, Brilinta, or Effient in combination with aspirin because she had surgery of stent placement and history of MI. In additional, Mrs. Allen needs to take Furosemide, because she experiences shortness of breath and pitting edema of the lower extremities. Patients, who has history of MI needs to take ACE inhibitors if they have no contraindications to it. Since Mrs. Allen is African-American, she may not tolerate ACE inhibitor and may develop allergic reaction (dry cough or swelling of the lips, tongue, face, or throat). In this case she needs to take Angiotensin receptor blockers (Mercado, Smith, & Macconnon, 2013).  

                              Conclusively, there is no doubt that Mrs. Allen requires urgent medical intervention. There are social-economic concerns such as financial constraints to afford medication. The ACC/AHA guideline stipulates the ideal mechanisms to help alleviate the suffering of such patients. Additional complications on the part of the patient require a cautious approach to medication, especially in regards to dosage (Ross, Shah, & Leeper, 2016). The guidelines and framework for patients with Arteriosclerotic Cardiovascular Disease is the most realistic path to Mrs. Allen’s positive health outcomes.